‘Agile’ Approach Aims To Accelerate Ridgeback’s COVID-19 Timeline
UK Leading On Innovative Adaptive Trials
Executive Summary
The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.
You may also be interested in...
Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
Coronavirus Update: Will Dexamethasone Breakthrough Make Remdesivir Irrelevant?
The RECOVERY trial has produced clear results for the cheap steroid treatment dexamethasone. What does it mean for Gilead's antiviral remdesivir?
Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition
While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.